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ess: j.c.virchow@med.uSummary Several clinical studies have confirmed the effectiveness of montelukast
10mg orally in adults with both asthma and allergic rhinitis. The objective of this
phase IV study was to investigate the efficacy and safety of montelukast 10mg in
adults with both asthma and allergic rhinitis in a real-life setting. Data from 5855
patients (mean age: 42.8715.4 years) were collected and analyzed following
treatment for 46 weeks. Efficacy was analyzed by comparing baseline values of:
general, day- and night-time improvement in asthma symptoms, need for rescue
medication or inhaled corticosteroids (ICSs), general and specific improvement in
allergic rhinitis symptoms, reduction in rhinitis medication use, and general and
specific quality of life (QoL) improvement with values collected at the end of the
observation period of 4–6 weeks. Following treatment with 10mg montelukast 86.5%
ðn ¼ 4547Þ of patients reported a strong or marked improvement in day-time asthma
symptoms and 88.5% ðn ¼ 4367Þ reported improvement in night-time symptoms. A
similarly high proportion of patients had a strong or marked improvement in all
symptoms of allergic rhinitis (i.e. sneezing/itching (84%), rhinorrhea (81.7%), nasal
congestion (79.3%), watery eyes (78.4%) and red or burning eyes (77.7%). The use of
asthma and rhinitis medication was also reduced. 92.3% ðn ¼ 5685Þ of all patients
intended to continue montelukast therapy. Overall QoL was ‘‘very good’’ or ‘‘good’’
in 85.2% of patients ðn ¼ 4991Þ and a ‘‘strong’’ or ‘‘marked’’ improvement in each of
the four domains of sleep, work, everyday life and physical activity. Montelukast was
well tolerated. Adverse drug reactions occurred in 14 out of 6158 patients. None of
the adverse events was serious. Accordingly, montelukast 10mg is a safe and
effective treatment for patients with both asthma and allergic rhinitis.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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The prevalence of asthma and allergic rhinitis has
risen markedly worldwide in recent years.1 Asthma is
estimated to affect 4–11% of the general popula-
tion, while allergic rhinitis is estimated to affect
between 10% and 30% of the general population.2,3
Comorbidity of asthma and rhinitis has been well
documented, suggesting a link between upper and
lower airway disease and the hypothesis that asthma
and rhinitis represent a systemic disease (i.e. one
airway one disease).4–6 The finding of nasal inflam-
mation in asthma and bronchial inflammation and
hyperresponsiveness in rhinitis further supports this
hypothesis.4–6 The majority of patients with asthma
also suffers from allergic rhinitis. It has been reported
that up to 80% of patients with asthma also have
rhinitis,7 while a significant number of patients with
rhinitis also have asthma.7,8 In patients with asthma
and allergic rhinitis healthcare costs are significantly
increased while quality of life (QoL) is significantly
worse.9–11 In addition, patients with rhinitis have an
increased risk of developing asthma.12,13
The Allergic Rhinitis and its Impact on Asthma (ARIA)
Guidelines categorize patients’ allergic rhinitis as
either ‘‘intermittent’’ or ‘‘persistent’’ with regards
to duration.14 The severity of allergic rhinitis is
subdivided into ‘‘mild’’ or ‘‘moderate-severe’’, de-
pending on symptoms and QoL.14 These guidelines
suggest to use combined strategies for the treatment
of upper and lower airways. They propose a stepwise
approach according to symptom severity and treat-
ment response. Leukotriene antagonists, such as
montelukast, were included in these guidelines as a
treatment option for allergic rhinitis14 despite the fact
that clinical studies about their efficacy were limited
at the time of publication.
Since cysteinyl leukotrienes participate in the
pathophysiology of both asthma and allergic rhinitis15
it has been suggested that blocking the cysteinyl
leukotriene receptor might be beneficial to patients
with asthma and allergic rhinitis.15 Accordingly, a
recent study has shown that montelukast can improve
symptoms of seasonal allergic rhinitis and asthma in
patients with both diseases.16 The aim of the present
article was to evaluate the efficacy and safety of add-
on montelukast (10mg orally) to existing controller
medication in the treatment of patients with asthma
and allergic rhinitis.Patients and methods
Study design
This multicentre, phase IV study with 3018 physi-
cians was designed to investigate the efficacy of10mg montelukast in adults with asthma and
allergic rhinitis. Current therapy for each patient
was recorded for 4–6 weeks of treatment be-
tween February 1st, 2004 and July 31st, 2004.
Patients
Patients were required to suffer from physician
diagnosed asthma and allergic rhinitis. The mini-
mum age of inclusion was 16 years. Montelukast
was either used as a monotherapy or in addition to
another anti-asthmatic therapy which was judged
to be inadequate prior to the administration of the
leukotriene receptor antagonist.
Baseline parameters
At visit 1 patients demographic data (gender and
age), disease diagnosis and severity were recorded.
Asthma severity was categorized according to
recent guidelines as ‘‘intermittent’’, ‘‘mild’’ or
‘‘moderate’’ and rhinitis was subdivided into
‘‘intermittent’’ or ‘‘persistent’’. Asthma daytime
symptoms (cough, wheezing, chest tightness and
shortness of breath) and night-time symptoms
(cough, shortness of breath and nocturnal awaken-
ings), the need for rescue medication and inhaled
corticosteroids (ICSs) were recorded together with
symptoms of allergic rhinitis (sneezing/itching,
runny nose, nasal congestion, watery eyes and
red/burning eyes). Any recent medication and its
perceived effectiveness to treat symptoms of
rhinitis were also recorded. In addition, patients’
overall QoL was assessed as ‘‘good’’, ‘‘satisfactory’’
or ‘‘reduced’’ and also more specifically according
to the four domains of ‘‘difficulty sleeping’’,
‘‘difficulty with work’’, ‘‘difficulty with everyday
life’’ and ‘‘limitation to daily activities’’.
Efficacy parameters
At the end of the observation period (4–6 weeks)
the following efficacy parameters were collected:
general improvement in asthma symptoms, im-
provement of day- and night-time asthma symp-
toms, need for rescue medication, need for ICSs,
general and specific improvement in allergic
rhinitis symptoms, reduction in medication to treat
the symptoms of allergic rhinitis, and general and
specific QoL improvement. General improvements
were categorized as ‘‘very good’’, ‘‘good’’, ‘‘satis-
factory’’, ‘‘sufficient’’ or ‘‘not sufficient’’. Specific
improvements in symptoms or QoL domains were
categorized as ‘‘strong’’, ‘‘marked’’, ‘‘moderate’’
or ‘‘none’’.
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Table 1 Patient baseline characteristics.
Characteristic n (%)
Gender
Male 2487 (42.5)
Female 3299 (56.3)
No data 69 (1.2)
Age (years)
Mean7standard deviation 42.8715.40
Range 16–96
Asthma severity
Intermittent 1728 (29.5)
Mild 1695 (29.0)
Moderate 2369 (40.5)
No data 63 (1.1)
Asthma symptoms in last weeks
Day-time symptoms 5256 (89.8)
Night-time symptoms 4930 (84.2)
Allergic rhinitis
Persistent 2754 (47.0)
Intermittent 3032 (51.8)
No data 69 (1.2)
Current rhinitis symptoms 5774 (98.6)
J.Chr. Virchow, C. Bachert1954Safety parameters
Undesirable effects (UE) and adverse drug effects
(ADE) were recorded during the treatment period
with montelukast 10mg.
Statistical analysis
The methods of descriptive statistics were em-
ployed to analyze results from this post-marketing
surveillance study and all analyses were performed
using SAS (Statistical Analysis System version 8.2 for
Windows). Case reports were considered evaluable
for efficacy (efficacy group) if the following criteria
were met: documented therapy with montelukast
(case report form filled out); data recorded for visit
2; patient aged at least 16 years; beginning of
monitored study medication not earlier than
February 1st, 2004. Case reports were considered
evaluable for drug safety (drug safety group) when
the following criteria were met: documented
therapy with montelukast 10mg. Undesirable
effects were calculated on the ‘‘preferred term’’
level.Table 2 Pre-study symptoms and quality of life
(QoL).
Characteristic n (%)
Day-time asthma symptoms
Cough 4381 (75)
Wheezing 2598 (44)
Chest tightness 2485 (42)
Shortness of breath 2166 (37)
Night-time asthma symptoms
Cough 3823 (65)
Shortness of breath 2062 (35)
Nocturnal awakening 3378 (58)
Allergic rhinitis symptoms
Sneezing/itching 5521 (94)
Running nose 5218 (89)
Congested nose 4646 (79)
Watery eyes 5052 (86)
Red/burning eyes 4507 (77)
Overall QoL assessment
Good 196 (3)
Satisfactory 1518 (26)
Reduced 4089 (70)
Individual QoL assessment
Difficulty sleeping 5509 (94)
Difficulty with job 5262 (90)
Difficulty with everyday life 5639 (96)
Limitations to daily activities 5610 (96)Results
Study population
In total, 6158 patients were identified by 3018
physicians. In all, 303 of these patients were not
included into the study due to prior treatment with
montelukast ðn ¼ 140Þ, ageo16 years ðn ¼ 175Þ or
missing data at visit 2 ðn ¼ 4Þ. Patients (5855)
(n ¼ 2487 male; n ¼ 3299 female) with a mean age
of 42.8715.4 years met all inclusion criteria and
were included in this post-marketing surveillance
study (Table 1). The average duration of observa-
tion was 5.5 weeks.
The majority of patients (40.5%) had moderate
asthma with both day- and night-time symptoms
in the last weeks prior to enrolment (Table 1).
Cough was the most frequently reported day-
and night-time symptom; more than half of the
patients (58%) had nocturnal awakenings due to
asthma (Table 2). There was a fairly even spread
of patients with intermittent and persistent
allergic rhinitis (51.8% and 47.0%, respectively);
almost all patients reported symptoms of allergic
rhinitis in the weeks prior to enrolment (Table 1),
namely sneezing/itching, rhinorrhea, nasal con-
gestion, watery eyes and/or red/burning eyes.
In 70% of all patients overall QoL was reduced
due to symptoms of asthma and rhinitis; most
patients reported difficulty sleeping, work-related
ARTICLE IN PRESS
Difficulty sleeping
Mild Moderate Severe
0
10
20
30
40
50
60
70
Degree of limitation
n
 (%
)
Difficulty with job
Mild Moderate Severe
0
10
20
30
40
50
60
70
Degree of limitation
n
 (%
)
Difficulty with everyday life
Mild Moderate Severe
0
10
20
30
40
50
60
70
Degree of limitation
n
 (%
)
Limitation of physical activity
Mild Moderate Severe
0
10
20
30
40
50
60
70
Degree of limitation
n
 (%
)
Figure 1 Pre-study degree of quality of life limitation.
Montelukast in allergic rhinitis and asthma 1955problems, impairments during everyday life and a
limitation in daily activities due to asthma and/or
rhinitis (Table 2 and Fig. 1). Well over half (58%) of
the patients reported a moderate limitation in each
of the four QoL domains while 16.8% of patients
reported severe impairment in sleeping, 10.9%
had severe work-related difficulties and 10.8%
and 22.1% of patients reported severe limitations
in their every day lives and physical activity,
respectively (Fig. 1).Efficacy results
Asthma symptoms
Following treatment with 10mg montelukast there
was an overall improvement in asthma symptoms in
the majority of patients, where 36.6% ðn ¼ 2143Þ
rated this improvement as ‘‘very good’’, and 45.2%
ðn ¼ 2648Þ as ‘‘good’’ (Fig. 2). Day-time symptoms
improved ‘‘strongly’’ or ‘‘markedly’’ in 86.5% ðn ¼
4547Þ of patients and 88.5% ðn ¼ 4367Þ reported an
improvement in night-time symptoms (Fig. 2). This
was accompanied by a reduction in the require-
ment for other asthma medications such as ß2-
agonists and ICSs. The number of patients who
needed additional asthma medication decreased by
19.9% ðn ¼ 1; 163Þ for ß2-agonist use and by 14.8%
ðn ¼ 865Þ for ICS use; in addition, the mean numberof puffs per day of ß2-agonists was reduced from
4.0 to 1.9 and from 2.5 to 1.6 for ICSs.Allergic rhinitis symptoms
Adding montelukast 10mg to current asthma
medication led to an overall improvement in
allergic rhinitis symptoms in 86.5% of patients;
37.7% ðn ¼ 2210Þ rated this improvement as ‘‘very
good’’ and 45.8% ðn ¼ 2684Þ as ‘‘good’’ (Fig. 3).
Most patients reported a ‘‘strong’’ or ‘‘marked’’
improvement in all symptoms of allergic rhinitis;
77.7% ðn ¼ 3502Þ reported a ‘‘strong’’ or ‘‘marked’’
improvement in red/burning eyes, 78.4% ðn ¼ 3961Þ
had a ‘‘strong’’ or ‘‘marked’’ improvement in
watery eyes, and 79.3% ðn ¼ 3682Þ reported similar
improvement in nasal congestion, while 81.7% ðn ¼
4266Þ had a ‘‘strongly’’ or ‘‘markedly’’ improved
rhinorrhea and 84% ðn ¼ 4637Þ similarly improved
sneezing/itching (Fig. 3). This was accompanied by
a reduction in rhinitis medication in 88.1% ðn ¼
4228Þ of all patients ðn ¼ 5855Þ. The strongest
decrease was observed for nasal steroids with 77.1%
(n ¼ 1566 of a total of 2031 patients). The use of a-
sympaticomimetics was reduced in 75.9% of pa-
tients (n ¼ 576 of a total of 759 patients), the use
of eye drops in 69% of patients (n ¼ 1616 of a total
of 2311 patients), anti-histamines in 69% of
patients (n ¼ 2499 of a total of 3621 patients) and
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Figure 2 Improvement in asthma. Sat: satisfactory; Suff:
sufficient.
J.Chr. Virchow, C. Bachert1956other rhinitis medications in 67.1% of patients
(n ¼ 336 of a total of 501 patients).
Quality of life
There was a ‘‘very good’’ or ‘‘good’’ improvement
in 85.2% of patients ðn ¼ 4991Þ in overall QoL and a
‘‘strong’’/‘‘marked’’ improvement in each of the
four domains of sleep, work, everyday life and
physical activity in 86.3% ðn ¼ 4752Þ, 81.6%ðn ¼ 4293Þ, 84.4% ðn ¼ 4764Þ and 82.1% ðn ¼ 4605Þ
of patients, respectively (Fig. 4).
Other efficacy results
Almost all patients (92.3%, n ¼ 5685) planned to
continue montelukast therapy after the end of the
observation period, while only 7.2% of patients ðn ¼
442Þ discontinued montelukast. In 2.6% ðn ¼ 160Þ
further treatment was not required due to either
almost completely resolved symptoms or due to the
fact that the hay fever season had ended. A
similarly large percentage (2.3%, n ¼ 142) discon-
tinued therapy due to insufficient efficacy and 0.2%
ðn ¼ 10Þ due to adverse events. 2.1% ðn ¼ 130Þ
reported other or no reason for discontinuation.
Safety results
Montelukast was well tolerated in this large phase
IV study. In 14 of 6158 patients (0.23%) 21 drug-
related adverse events were reported. Most fre-
quently headache, gastrointestinal infections and
sleepiness were observed as single symptoms. None
of the adverse events was serious.Discussion
Asthma and allergic rhinitis have been linked
clinically for many years. This has recently been
acknowledged in the ‘‘one airway one disease’’
concept which underlines the hypothesis that both
diseases share a common pathophysiology, char-
acterized by inflammation of the respiratory
mucosa by the same pro-inflammatory cells (e.g.
eosinophils, Th2 lymphocytes and mast cells) and
mediators (e.g. cytokines, histamine and leuko-
trienes).4,5,17 Patients with asthma and rhinitis are
twice as likely to require emergency care for
asthma, and need more asthma-related hospitali-
zations and GP visits leading to higher asthma drug
costs. In addition, patients with allergic asthma and
rhinitis are significantly more likely to experience
asthma attacks compared to patients with asthma
alone.11,18 Based on these findings it has been
suggested that both conditions should be ideally
treated together.14 Montelukast, a leukotriene
receptor antagonist, has been shown to improve
both asthma and allergic rhinitis symptoms 15,16,21
and therefore has the potential to conveniently
treat patients with asthma and rhinitis.19,20
In this phase IV study treatment with montelu-
kast 10mg for 4–6 weeks (added to existing
controller medication) was effective and well
tolerated in patients with mild-to-moderate
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Figure 3 Improvement in rhinitis. Sat: satisfactory; Suff: sufficient.
Montelukast in allergic rhinitis and asthma 1957asthma and allergic rhinitis. There was a ‘‘strong’’
or ‘‘marked’’ improvement in both day- and night-
time asthma symptoms as well as the symptoms of
allergic rhinitis. These improvements were asso-
ciated with a reduction in both asthma and rhinitis
medication. Similar results have been previously
reported from studies in which montelukast was
added to existing therapies.16,21 Accordingly, a
subgroup analysis from the Clinical Outcomes with
Montelukast as a Partner Agent to Corticosteroid
Therapy (COMPACT) study21 suggested that the
mean increase in pulmonary function in patients
with persistent asthma and a physician-based
diagnosis of allergic rhinitis was greater when
montelukast was added to a previous regimen of
800 mg of budesonide/day versus doubling the dose
of budesonide to 1600 mg/day.21 Adding montelu-kast to existing maintenance therapy also signifi-
cantly improved the symptoms of seasonal allergic
rhinitis in patients with concomitant active asth-
ma.16 Furthermore, the addition of montelukast
significantly ðPo0:001Þ reduced daily rhinitis symp-
tom scores, day-time nasal symptoms, nasal con-
gestion, rhinorrhea and sneezing, night-time
symptoms, especially nasal congesting upon awa-
kening and day-time eye symptoms.16 Both patients
and physicians also reported significant improve-
ments in the global evaluation of allergic rhinitis
ðPp0:001Þ and asthma ðPp0:05Þ. Similar to our
findings patients who took montelukast needed
significantly less rescue medication which is likely
to impact on healthcare resource use16 as has been
suggested by a study from Italy in children under 14
years of age where montelukast decreased the
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Figure 4 Improvement in quality of life (QoL). Sat: satisfactory; Suff: sufficient.
J.Chr. Virchow, C. Bachert1958total use and costs of asthma rescues/acute and
allergy medication over a 2-year period.22 The
results of these studies which are now expanded
with our post-marketing surveillance study, add
further proof to the effectiveness of montelukast
not only in a clinical setting, but also in a real-life
setting.
Both asthma and allergic rhinitis can impair QoL
which is further reduced in patients with both
diseases.10 Patients treated in an open label setting
with montelukast 10mg orally reported a
‘‘strong’’/‘‘marked’’ improvement in their QoL
most notably in the domains of sleep, work,
everyday life and physical activity. Similar results
have been obtained from controlled trials16 which
also showed that montelukast treatment improvedrhinoconjunctivitis QoL overall score in
patients with both asthma and allergic rhinitis.
Significant (Po0:05 each) improvements were
noted in the QoL domains of nasal symptoms, eye
symptoms, activity, sleep, emotions and practical
problems.16
In conclusion, based on previous findings asthma
and allergic rhinitis often occur together and
common treatment strategies have been recently
suggested for both diseases. Our findings from a
very large number of patients suggest that previous
results from smaller, randomized controlled trials
can be translated into a real-life setting, where
montelukast is a safe and effective systemic
treatment of both upper and lower airways in
patients with both asthma and allergic rhinitis.
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